

Special Issue

Foot and Mouth Disease Virus and Novel Vaccines Developments

Message from the Guest Editor

Foot-and-mouth disease (FMD) is a contagious vesicular disease caused by a highly variable RNA virus (FMDV) affecting cloven-hoofed animals with severe social and economic consequences worldwide. Chemically inactivated whole virus vaccines have been used to contain the disease, but are slow acting and do not always permit distinction between infected and vaccinated animals. New rapid vaccines and emergency response measures, such as therapeutics, need to be developed to allow for rapid containment of future FMDV outbreaks in addition to methods that distinguish between infected and vaccinated animals. This Special Issue will cover FMDV determinant of replication and pathogenesis and how this information has facilitated next-generation FMDV vaccine and biotherapeutic developments. We particularly encourage the submission of manuscripts focused on improved control strategies addressing important gaps of the current inactivated FMDV vaccine including, but not limited to, duration of immunity, crossreactivity, correlates of protection, early protection, antigen load, immunization responses, and safer marker vaccines.

Guest Editor

Dr. Elizabeth Rieder

Foreign Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, Plum Island Animal Disease Center, Greenport, NY 11944, USA

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/42230

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).